Cargando…

Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer

BACKGROUND: Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE(1)) and 16-hydroxyestrone (16-OHE(1)) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer. METHODS: This population-based study was initiated...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Tengteng, Nichols, Hazel B, Nyante, Sarah J, Bradshaw, Patrick T, Moorman, Patricia G, Kabat, Geoffrey C, Parada, Humberto, Khankari, Nikhil K, Teitelbaum, Susan L, Terry, Mary Beth, Santella, Regina M, Neugut, Alfred I, Gammon, Marilie D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236781/
https://www.ncbi.nlm.nih.gov/pubmed/32455334
http://dx.doi.org/10.1093/jncics/pkaa014
_version_ 1783536211942440960
author Wang, Tengteng
Nichols, Hazel B
Nyante, Sarah J
Bradshaw, Patrick T
Moorman, Patricia G
Kabat, Geoffrey C
Parada, Humberto
Khankari, Nikhil K
Teitelbaum, Susan L
Terry, Mary Beth
Santella, Regina M
Neugut, Alfred I
Gammon, Marilie D
author_facet Wang, Tengteng
Nichols, Hazel B
Nyante, Sarah J
Bradshaw, Patrick T
Moorman, Patricia G
Kabat, Geoffrey C
Parada, Humberto
Khankari, Nikhil K
Teitelbaum, Susan L
Terry, Mary Beth
Santella, Regina M
Neugut, Alfred I
Gammon, Marilie D
author_sort Wang, Tengteng
collection PubMed
description BACKGROUND: Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE(1)) and 16-hydroxyestrone (16-OHE(1)) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer. METHODS: This population-based study was initiated in 1996–1997 with spot urine samples obtained shortly after diagnosis (mean = 96 days) from 683 women newly diagnosed with first primary breast cancer and 434 age-matched women without breast cancer. We measured urinary concentrations of 2-OHE(1) and 16-OHE(1) using an enzyme-linked immunoassay. Vital status was determined via the National Death Index (n = 244 deaths after a median of 17.7 years of follow-up). We used multivariable-adjusted Cox proportional hazards to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the estrogen metabolites-mortality association. We evaluated effect modification using likelihood ratio tests. All statistical tests were two-sided. RESULTS: Urinary concentrations of the 2-OHE(1) to 16-OHE(1) ratio (>median of 1.8 vs ≤median) were inversely associated with all-cause mortality (HR = 0.74, 95% CI = 0.56 to 0.98) among women with breast cancer. Reduced hazard was also observed for breast cancer mortality (HR = 0.73, 95% CI = 0.45 to 1.17) and cardiovascular diseases mortality (HR = 0.76, 95% CI = 0.47 to 1.23), although the 95% confidence intervals included the null. Similar findings were also observed for women without breast cancer. The association with all-cause mortality was more pronounced among breast cancer participants who began chemotherapy before urine collection (n = 118, HR = 0.42, 95% CI = 0.22 to 0.81) than among those who had not (n = 559, HR = 0.98, 95% CI = 0.72 to 1.34; P(interaction) = .008). CONCLUSIONS: The urinary 2-OHE(1) to 16-OHE(1) ratio may be inversely associated with long-term all-cause mortality, which may depend on cancer treatment status at the time of urine collection.
format Online
Article
Text
id pubmed-7236781
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72367812020-05-22 Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer Wang, Tengteng Nichols, Hazel B Nyante, Sarah J Bradshaw, Patrick T Moorman, Patricia G Kabat, Geoffrey C Parada, Humberto Khankari, Nikhil K Teitelbaum, Susan L Terry, Mary Beth Santella, Regina M Neugut, Alfred I Gammon, Marilie D JNCI Cancer Spectr Article BACKGROUND: Estrogen metabolite concentrations of 2-hydroxyestrone (2-OHE(1)) and 16-hydroxyestrone (16-OHE(1)) may be associated with breast carcinogenesis. However, no study has investigated their possible impact on mortality after breast cancer. METHODS: This population-based study was initiated in 1996–1997 with spot urine samples obtained shortly after diagnosis (mean = 96 days) from 683 women newly diagnosed with first primary breast cancer and 434 age-matched women without breast cancer. We measured urinary concentrations of 2-OHE(1) and 16-OHE(1) using an enzyme-linked immunoassay. Vital status was determined via the National Death Index (n = 244 deaths after a median of 17.7 years of follow-up). We used multivariable-adjusted Cox proportional hazards to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the estrogen metabolites-mortality association. We evaluated effect modification using likelihood ratio tests. All statistical tests were two-sided. RESULTS: Urinary concentrations of the 2-OHE(1) to 16-OHE(1) ratio (>median of 1.8 vs ≤median) were inversely associated with all-cause mortality (HR = 0.74, 95% CI = 0.56 to 0.98) among women with breast cancer. Reduced hazard was also observed for breast cancer mortality (HR = 0.73, 95% CI = 0.45 to 1.17) and cardiovascular diseases mortality (HR = 0.76, 95% CI = 0.47 to 1.23), although the 95% confidence intervals included the null. Similar findings were also observed for women without breast cancer. The association with all-cause mortality was more pronounced among breast cancer participants who began chemotherapy before urine collection (n = 118, HR = 0.42, 95% CI = 0.22 to 0.81) than among those who had not (n = 559, HR = 0.98, 95% CI = 0.72 to 1.34; P(interaction) = .008). CONCLUSIONS: The urinary 2-OHE(1) to 16-OHE(1) ratio may be inversely associated with long-term all-cause mortality, which may depend on cancer treatment status at the time of urine collection. Oxford University Press 2020-03-02 /pmc/articles/PMC7236781/ /pubmed/32455334 http://dx.doi.org/10.1093/jncics/pkaa014 Text en © The Author(s) 2020. Published by Oxford University Press. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Wang, Tengteng
Nichols, Hazel B
Nyante, Sarah J
Bradshaw, Patrick T
Moorman, Patricia G
Kabat, Geoffrey C
Parada, Humberto
Khankari, Nikhil K
Teitelbaum, Susan L
Terry, Mary Beth
Santella, Regina M
Neugut, Alfred I
Gammon, Marilie D
Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title_full Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title_fullStr Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title_full_unstemmed Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title_short Urinary Estrogen Metabolites and Long-Term Mortality Following Breast Cancer
title_sort urinary estrogen metabolites and long-term mortality following breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236781/
https://www.ncbi.nlm.nih.gov/pubmed/32455334
http://dx.doi.org/10.1093/jncics/pkaa014
work_keys_str_mv AT wangtengteng urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT nicholshazelb urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT nyantesarahj urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT bradshawpatrickt urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT moormanpatriciag urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT kabatgeoffreyc urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT paradahumberto urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT khankarinikhilk urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT teitelbaumsusanl urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT terrymarybeth urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT santellareginam urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT neugutalfredi urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer
AT gammonmarilied urinaryestrogenmetabolitesandlongtermmortalityfollowingbreastcancer